THAT.LSE Thalia Therapeutics Plc
- Market cap
- GBX 10.7M
- P/E
- -
- P/B
- 4.15x
- ROE
- -122.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is THAT.LSE undervalued?
Graham numberThe Graham number of Thalia Therapeutics Plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Thalia Therapeutics Plc fundamental analysis
No fundamental analysis for Thalia Therapeutics Plc yet.
Thalia Therapeutics Plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Thalia Therapeutics Plc
Thalia Therapeutics Plc, a biotechnology company, develops and delivers RNA-based therapeutics and technologies in oncology and cardiovascular disease in the United Kingdom. The company develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines. It also develops Nuvec, a pipeline of RNA therapeutics; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also en…
Full company profileThalia Therapeutics Plc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Thalia Therapeutics Plc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.16M | - | - | - | - | 0.00 | 0.00 | 1.95K | 7.28K | 7.26K | 14.6K |
| Gross Profit | 221K | - | - | - | - | - | - | 1.95K | 7.28K | 7.26K | - |
| Operating Income | -28.0K | -726K | -1.49M | -947K | -1.56M | -1.84M | -1.19M | -1.43M | -1.22M | -1.10M | -3.03M |
| EBITDA | -185K | -1.92M | -1.42M | -947K | -1.56M | -1.84M | -1.19M | -1.34M | -1.22M | -1.10M | -3.03M |
| Net Income | -22.0K | -1.84M | -1.19M | -876K | -1.31M | -1.54M | -1.03M | -1.27M | -1.06M | -1.21M | -3.02M |
| EPS | 0.00 | -0.03 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 1.12M | 1.46M | 1.07M | 1.07M | 3.83M | 2.34M | 2.17M | 1.28M | 776K | 1.17M | 2.71M |
| Total Liabilities | 77.0K | 179K | 190K | 77.7K | 169K | 213K | 77.9K | 81.7K | 124K | 98.0K | 246K |
| Shareholders' Equity | 1.04M | 1.28M | 880K | 987K | 3.66M | 2.13M | 2.09M | 1.13M | 648K | 1.07M | 2.46M |
| Cash & Short-term Investments | 172K | 1.33M | 793K | 966K | 3.56M | 1.78M | 1.92M | 1.03M | 626K | 1.08M | 1.50M |
| Total Debt | 205K | - | - | - | - | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -376K | -951K | -1.34M | -806K | -1.38M | -1.77M | -828K | -1.21M | -972K | -1.16M | -2.98M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 | 0.00 | 0.00 | 5.00 | 0.00 |
| Free Cash Flow | -376K | -951K | -1.34M | -806K | -1.38M | -1.77M | -828K | -1.21M | -972K | -1.16M | -2.98M |
| Ratios | |||||||||||
| ROE | -2.1% | -143.5% | -134.7% | -88.7% | -35.7% | -72.5% | -49.3% | -112.5% | -163.5% | -112.6% | -122.7% |
| ROA | -2.0% | -125.9% | -110.7% | -82.3% | -34.1% | -65.9% | -47.5% | -99.5% | -136.5% | -103.1% | -111.6% |
| Net Profit Margin | -1.9% | - | - | - | - | - | - | -64,977.0% | -14,542.7% | -16,589.9% | -20,728.5% |
| Debt to Equity | 0.20x | - | - | - | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Thalia Therapeutics Plc dividends
Thalia Therapeutics Plc has not paid dividends in the last 9 fiscal years.
Last stock split: 200:800 on May 3, 2017.
Who owns Thalia Therapeutics Plc
- Insiders 58.65%
- Institutions 1.88%
- Public & others 39.47%
- Shares outstanding 1.78B
- Free float 714M
Thalia Therapeutics Plc company profile
- Company name
- Thalia Therapeutics Plc
- Ticker
- THAT.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3
- Fiscal year end
- December
- Address
- 2 Portman Street, London, United Kingdom, W1H 6DU
- Phone
- 44 20 4610 0714
- Website
- thaliatx.com
About Thalia Therapeutics Plc
Thalia Therapeutics Plc, a biotechnology company, develops and delivers RNA-based therapeutics and technologies in oncology and cardiovascular disease in the United Kingdom. The company develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines. It also develops Nuvec, a pipeline of RNA therapeutics; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also engages in the development of N4 101, an orally delivered inflammation inhibitor for treatment of inflammatory bowel disease; and ECP105 for the prevention of ocular scarring. The company has collaboration with the Centre for Continuous Manufacturing and Advanced Crystallisation at the University of Strathclyde to support the scale-up and characterisation of Nuvec. The company was formerly known as N4 Pharma Plc and changed its name to Thalia Therapeutics Plc in March 2026. Thalia Therapeutics Plc was incorporated in 1979 and is based in London, the United Kingdom.
Thalia Therapeutics Plc management
7- Mr. Luke Sebastian CairnsExecutive Director · born 1978
- Dr. David Horn Solomon M.D.CEO & Executive Director · born 1960
- Rob HarrisHead of CMC Development
- Dr. Fiona McLaughlin FSB, Ph.D.Head of Research & Development · born 1970
- Mr. Mark Edbrooke Ph.D.Head of Strategy
- Dr. Margaret Courtney Ph.D.Head of Chemistry, Manufacturing & Controls
- Dr. Andrew LeishmanConsultant